Comparative efficacy and safety of two 0.025% tretinoin gels: Results from a multicenter, double-blind, parallel study - 09/09/11
Abstract |
Background: The addition of polyolprepolymer-2 in tretinoin formulations may reduce tretinoin-induced cutaneous irritation. Objective: This study compared the efficacy and safety of a new 0.025% tretinoin gel containing polyolprepolymer-2, its vehicle, and a commercially-available 0.025% tretinoin gel in patients with mild to moderate acne vulgaris. Methods: In this 12-week multicenter, double-blind, parallel group study, efficacy was evaluated by objective lesion counts and the investigators’ global evaluations. Subjective assessment of cutaneous irritation by the investigators and patients evaluated safety. Results: The efficacy of the two active treatments in this 215 patient study was comparable, and both treatments were statistically significantly more effective than vehicle. When compared with the commercially-available tretinoin gel, the formulation containing polyolprepolymer-2 demonstrated statistically significantly less peeling at days 28, 56, and 84, statistically significantly less dryness by day 84, and statistically significantly less itching at day 14. Irritation scores for the formulation containing polyolprepolymer-2 were numerically lower but not statistically different from those of the commercially-available gel for erythema and burning. The number of cutaneous and noncutaneous adverse events were similar for both active medications. Conclusion: The two 0.025% gels studied demonstrated comparable efficacy. However, the gel formulation containing polyolprepolymer-2 caused significantly less peeling and drying than the commercially-available formulation by day 84 of the study. (J Am Acad Dermatol 1998;38:S17-23.)
Le texte complet de cet article est disponible en PDF.Plan
Reprint requests: Anne W. Lucky, MD, Dermatology Research Associates, 7691 Five Mile Road, Cincinnati, OH 45230. |
|
0190-9622/98/$5.00 + 0 16/0/88701 |
Vol 38 - N° 4
P. S17-S23 - avril 1998 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?